SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Novoste (novt) -- Ignore unavailable to you. Want to Upgrade?


To: dr.john who wrote (70)7/30/1999 8:08:00 AM
From: Oak Tree  Respond to of 100
 
I agree with you completely. Cardiologists love IVUS. They can see what they are doing clearly instead of guessing based on floro. It takes more than a few minutes and its a thousand dollar plus throw away item. In the end of the day they have done one less cath and spent several $1000. Also, they sometimes have to later prove to the blues that the patient needed it -- wasting more time. In the end they have lost a megabuck a year per cath lab. Perhaps if there was reimbursement for IVUS and they even had a markup, IVUS would become standard. My cardiologist friends would love to do IVUS on everyone -- they actually do very few and most of those are on protocols wherein the IVUS costs are covered.



To: dr.john who wrote (70)12/29/1999 8:37:00 AM
From: Oak Tree  Read Replies (1) | Respond to of 100
 
dr. john,
Looks like novoste will not be the first on the market. Being first counts especially if the research data for beta is not as clean as that for gamma. NOVT may be in more trouble. I suspect however NOVT may benefit from Jan effect so I'm not selling short yet.
Oak